Imagion Biosystems Limited announces it has entered into a collaboration agreement with Siemens Healthcare Pty Ltd of Australia (Siemens Healthineers) to further explore the utility
Imagion Biosystems Limited is pleased to share news of a recent publication, led by researchers at the Weill Cornell Medical College, which reports use of
Imagion Biosystems Limited is pleased to provide investors with its May 2020 Investor Newsletter. The newsletter details recent key company developments and activities including: Message
Imagion Biosystems Limited has announced “Appendix 3X: Initial Director’s Interest Notice.” Read Appendix 3X.
Imagion Biosystems Limited today announced the appointment of Ms Dianne Angus to the Board of Directors. Ms Angus joined the Board as a Non-Executive Director
Five Appendices 3Y, “Change of Director’s Interest Notice”, have been released to announce the entitlement right offers taken up by Imagion Directors. Read the Appendices
Imagion Biosystems has released Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations. Read Appendix 4G
Imagion Biosystems has released its Annual Report to Shareholders for the year ended 31 December 2019. Read the Annual Report.
Imagion Biosystems announces that Appendix 2A – Vesting of Performance Rights has been released to the market. Read Appendix 2A – Vesting of Performance Rights.
Imagion Biosystems has announced Appendix 2A — Application for quotation of +securities. Read Appendix 2A.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance